The Health Transformation Alliance says 83% of type 2 diabetes patients who didn't improve stayed on therapy, versus 94% of good responders, as employers rethink 2027 coverage.
Recap by typeshit. Full story at HRD America.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
18:20
Dr. Lindsay Ogle, an MD who covers metabolic health, talks through options for people whose appetite hasn't settled on GLP-1 treatment.
A short post credits scientists with finding axolotl peptides that kill breast cancer cells. It names no study or team, so treat it as an early claim.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
The Sun tallies possible side effects tied to Lilly's experimental triple agonist, including bladder problems and anxiety. Worth checking how the list was built.
Tirzepatide drew 186 reports through 21 September as pharmacy supply jumped past 395,000 packs by June. Nausea topped the list, with 19 pancreatitis-linked cases since 2024.
Loading…